China Pharma Holdings, Inc. reported a revenue of $4.1 million for the fiscal year ending December 31, 2025, a decrease of $0.4 million from $4.5 million in 2024. This decline is attributed to increased competition from other pharmaceutical providers included in the national centralized procurement (CP) program, which Helpson's products could not participate in due to not passing the required consistency evaluations. The company's gross loss improved to $0.1 million, with a gross loss margin of 3.2%, compared to a gross loss of $2.0 million and a margin of 43.8% in the previous year. The reduction in gross loss was primarily due to lower depreciation expenses and a decrease in inventory obsolescence.
In terms of product categories, the "Anti-Viral/Infection & Respiratory" segment saw the most significant revenue drop, generating $2.48 million in 2025, down from $2.75 million in 2024. The "CNS Cerebral & Cardio Vascular" category also experienced a slight decline, while the "Digestive Diseases" category reported a modest increase in sales. The company generated $33,227 in revenue from its Contract Manufacturing Organization (CMO) services, marking a new revenue stream as it undertakes R&D and production for external clients.
Operationally, China Pharma's total cost of revenue decreased to $4.3 million, or 103.2% of total revenue, down from $6.5 million in 2024. Selling expenses also fell to $0.38 million, while general and administrative expenses rose to $2.45 million, largely due to increased amortization expenses related to purchased patent technology. The company recorded a net loss of $3.19 million for 2025, an improvement from a net loss of $4.74 million in 2024, reflecting a decrease in overall expenses.
Looking ahead, China Pharma plans to enhance its sales model and strengthen its collection of accounts receivable. The company is also exploring strategic alternatives to accelerate the launch of comprehensive healthcare products, which are expected to generate additional revenue. However, there remains substantial doubt about the company's ability to continue as a going concern, as it has incurred recurring losses and has net current liabilities. Management is actively seeking to improve cash flow and operational efficiency to address these challenges.
About CHINA PHARMA HOLDINGS, INC.
China Pharma Holdings Inc., through its subsidiary Hainan Helpson Medical and Biotechnology Co., Ltd., develops, manufactures, and markets prescription pharmaceutical products in China. Its portfolio includes generic drugs, first-to-market generics, and modern Traditional Chinese Medicines targeting high-incidence diseases like cardiovascular, CNS, infectious, and digestive conditions. Operating GMP-certified facilities, Helpson sells primarily to hospitals and pharmacies via a national distribution network, leveraging academic-driven promotion and regulatory compliance to maintain competitive positioning in China’s pharmaceutical market.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.